Hepatobiliary Adverse Reactions during Treatment with Cladribine: Analysis of Data from the European Spontaneous Reporting System.

Elena Mirabela VelișcuValerio LiguoriAntonietta AnatrielloGiorgia Teresa ManiscalcoAndrea CantoneLuigi Di CostanzoPasquale StefanelliCristina ScavoneAnnalisa Capuano

Published in: Pharmaceuticals (Basel, Switzerland) (2023)

Considering the seriousness of cladribine-induced hepatic ADRs, a close monitoring of patients receiving this drug is highly recommended. In this context, further pharmacovigilance studies evaluating the hepatic safety profile of cladribine are strongly needed.

Keyphrases

adverse drug
electronic health record
drug induced
high glucose
diabetic rats
emergency department
big data
case control
endothelial cells
deep learning
stress induced